The Incremental Value of Diuretic Dose in Staging Systems for Transthyretin Cardiac Amyloid

The Incremental Value of Diuretic Dose in Staging Systems for Transthyretin Cardiac Amyloid

Bibliographic Details
Main Author:	Martha Grogan, MD
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	JACC. CardioOncology
Subjects:	cardiac amyloidosis heart failure transthyretin
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666087320301654

Similar Items

Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis
by: Richard K. Cheng, MD, MSc, et al.
Published: (2020-09-01)

Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
by: Richard K. Cheng, et al.
Published: (2021-12-01)

Clinical characteristics and natural history of wild‐type transthyretin amyloid cardiomyopathy in Japan
by: Toshihiro Yamada, et al.
Published: (2020-10-01)

Multiorgan Dysfunction and Associated Prognosis in Transthyretin Cardiac Amyloidosis
by: Adam Ioannou, et al.
Published: (2024-02-01)

Transthyretin amyloid cardiomyopathy. Features of histological diagnosis: study design
by: Valeriia V. Guselnikova, et al.
Published: (2022-05-01)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
by: Paolo Morfino, et al.
Published: (2023-04-01)

Frailty in heart failure according to the presence or absence of wild‐type transthyretin cardiac amyloidosis
by: Amaury Broussier, et al.
Published: (2025-02-01)

Incidence and predictors of worsening heart failure in patients with wild‐type transthyretin cardiac amyloidosis
by: Bertil Thyrsted Ladefoged, et al.
Published: (2022-10-01)

Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence‐Based Recommendations
by: Nuno Marques, et al.
Published: (2020-10-01)

Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data
by: Maximilian Leo Müller, et al.
Published: (2024-07-01)

Risk stratification in transthyretin-related cardiac amyloidosis
by: Riccardo Scirpa, et al.
Published: (2023-03-01)

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
by: Marianna Fontana, et al.
Published: (2023-11-01)

The Interpretation and Update of the Diagnosis Pathway of Chinese Expert Consensus on the Diagnosis and Treatment of Transthyretin Cardiac Amyoidosis
by: TIAN Zhuang, et al.
Published: (2023-01-01)

Hereditary systemic transthyretin amyloidosis: a clinical case and an opinion on the problem
by: A. S. Draganova, et al.
Published: (2019-07-01)

Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic
by: Krister Lindmark, et al.
Published: (2021-02-01)

Dapagliflozin treatment and cardiovascular outcome in RBP4/TTRVal30Met (transthyretin cardiac amyloidosis) mice
by: Zonglin Li, et al.
Published: (2024-02-01)

Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report
by: Hiroyuki Yamamoto, et al.
Published: (2018-12-01)

Transthyretin cardiac amyloidosis: an update on diagnosis and treatment
by: Hiroyuki Yamamoto, et al.
Published: (2019-12-01)

Diagnosis of Transthyretin Amyloid Cardiomyopathy
by: Adam S. Hafeez, et al.
Published: (2020-04-01)

Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond
by: Biobelemoye Irabor, et al.
Published: (2022-05-01)

Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP)
by: Fábio Fernandes, et al.
Published: (2024-07-01)

Impact of the Noninvasive Diagnostic Algorithm on Clinical Presentation and Prognosis in Cardiac Amyloidosis
by: Giacomo Tini, MD, et al.
Published: (2024-10-01)

Transthyretin cardiac amyloidosis in aortic stenosis: Prevalence, diagnostic challenges, and clinical implications
by: Giedre Balciunaite, et al.
Published: (2020-03-01)

Wild-Type Transthyretin Cardiac Amyloidosis in a Transplanted Heart
by: Lily K. Stern, MD, et al.
Published: (2023-08-01)

Coexistence of Light Chain and Transthyretin Cardiac Amyloidosis
by: Abhishek Gami, MD, et al.
Published: (2024-04-01)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
by: Stephan Dobner, et al.
Published: (2023-02-01)

Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction
by: Anouk Achten, et al.
Published: (2024-12-01)

Transthyretin amyloid cardiomyopathy: Treatment pipeline, clinical trials, and challenges
by: Sweety Sharma, et al.
Published: (2021-01-01)

Cardiac Amyloidosis-Challenging Diagnosis and Unclear Clinical Picture
by: Sylwia Kozak, et al.
Published: (2021-05-01)

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy
by: Pablo Garcia‐Pavia, et al.
Published: (2024-12-01)

Early diagnosis, disease stage and prognosis in wild‐type transthyretin amyloid cardiomyopathy: The DIAMOND study
by: Giacomo Tini, et al.
Published: (2025-02-01)

Is It Time for Population-Based Screening for Transthyretin Cardiac Amyloidosis?
by: Parag Goyal, MD, MSc, et al.
Published: (2024-10-01)

Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study
by: Yüksel Çavuşoğlu, et al.
Published: (2024-01-01)

Hereditary and wild type transthyretin amyloid cardiomyopathy in Bulgaria in patients suspected for cardiac amyloidosis
by: S. Stefanov, et al.
Published: (2024-09-01)

Wild-type Transthyretin Amyloid Deposition in an Ascending Aortic Aneurysm
by: Abbas Hoteit, MD, et al.
Published: (2024-05-01)

A clinical case of hereditary transthyretin amyloidosis. Case report
by: Anastasia A. Shoshina, et al.
Published: (2023-05-01)

Research trends and hotspots evolution of cardiac amyloidosis: a bibliometric analysis from 2000 to 2022
by: Zhenyue Fu, et al.
Published: (2023-02-01)

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
by: Alejandra González‐Duarte, et al.
Published: (2020-03-01)

Incidence and survival of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases
by: Thibaud Damy, et al.
Published: (2023-11-01)

Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis
by: Hiroki Yamaguchi, et al.
Published: (2022-03-01)